Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX: 6704)
Health Care · Biotechnology · TW
NT$19.20
+1.05% today · -15.6% 1Y
Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX: 6704) operates in the Biotechnology industry within the Health Care sector. The company is valued at $57.58M and employs 55 people.
Over the last twelve months the share price has lost 15.6%, trading between 18.15 and 33.65.
Tweenvest scores Gwo Xi Stem Cell Applied Technology Co. , Ltd across four factors: quality 41/100, value 55/100, growth 70/100. Its strongest factor is growth.
6704 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $57.58M
- Revenue (TTM)
- $5.96M
- P/E
- —
- EPS
- -0.84
- Dividend yield
- —
- Beta (5Y)
- 0.10
- 52-week high
- NT$33.65
- 52-week low
- NT$18.15
- Avg volume (3M)
- —
- Shares outstanding
- 95.95M
- Employees
- 55
- Next earnings
- —
About Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem cell-based therapies, addressing critical unmet medical needs in patient care. Its product pipeline currently features two pioneering autologous adipose-derived stem cell treatments: GXHPC1, which is in Phase II clinical trials for liver cirrhosis, and GXNPC1, also undergoing Phase II testing, designed for the management of chronic stroke. Further expanding its therapeutic portfolio, the company is advancing GXCPC1, an allogeneic adipose-derived stem cell therapy currently in combined Phase I/II clinical trials for osteoarthritis, alongside GXIPC1, another allogeneic fat-derived stem cell treatment in early-stage Phase I trials for diabetes. Established in 2011, the company maintains its headquarters in Zhubei, Taiwan.
- ISIN
- TW0006704000
- Founded
- 2011
- Listed since
- Apr 26, 2023
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.18 | -0.13% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.98 | +0.26% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.96 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.00 | +0.26% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.94 | +0.78% |
| argenx SEENXTBR: ARGX | $63.06B | €872.80 | +1.00% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $140.88 | +1.43% |
Figures last refreshed Aug 18, 2026.